Arecor Therapeutics

Panmure Gordon acted as Sole Bookrunner, Financial Adviser & Nominated Adviser on the IPO of Arecor Therapeutics plc.

• Offer price of 226p/£63m market cap on admission – oversubscribed £20m primary raise
• Arecor is a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products
• Admission to Trading on the AIM market of the London Stock Exchange took place on 3 June 2021

• Supported by a broad selection of high-quality investors
• 36 institutional investors & wealth managers on the share register on 1st day of dealing
• EIS/VCT Placing of £8.4m and General Placing of £11.6m

• A revenue generating biopharmaceutical company, bringing innovative medicines to market through the enhancement of existing therapeutic products
• Broad applicability of the platform technology across growing pharmaceutical markets, partnering with global pharmaceutical and biotechnology companies
• Reduced development risk and timelines, with the potential to receive royalties and milestone payments under a revenue generating licence model
• Strong management team and Board with significant experience in managing high growth companies, capable of executing a major value proposition in the specialty pharmaceutical field